Clinical trials with a prolonged follow-up ap- pear necessary to better evaluate the impact of this issue [53]. Baseline fasting glucose and other features of the metabolic syndrome, along with the use of high-dose statins in the elderly, seem to be the strongest predictors of new-onset T2DM. As a practical suggestion for the day-by- day clinical activity, it may be concluded that statins remain the corner- stone for primary and secondary CVD prevention, but, in light of the available data, a specific attention to glucose metabolism and metabolic syndrome features should be payed when evaluating a patient for such therapy as well as after statin treatment has been started.